AstraZeneca PLC (AZN)
Pre-Market:
| Previous Close | 76.97 |
| Open | 76.72 |
| Bid | 77.01 x 700 |
| Ask | 77.06 x 700 |
| Day's Range | 76.58 - 77.22 |
| 52 Week Range | 60.47 - 77.94 |
| Volume | |
| Avg. Volume | 5,515,259 |
| Market Cap | 238.86B |
| Beta (5Y Monthly) | 0.16 |
| PE Ratio (TTM) | 37.95 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.45 (1.88%) |
| Ex-Dividend Date | Feb 22, 2024 |
| 1y Target Est | N/A |
- Reuters
PRESS DIGEST-British Business - May 14
The following are the top stories on the business pages of British newspapers. - Anglo American rejected a raised takeover offer of 34 billion pounds ($42.67 billion) from BHP Group on Monday, saying the world's largest listed miner "continues to significantly undervalue" the company. - JPMorgan Chase has pledged a further 40 million pounds ($50.22 million) in philanthropic investments in the UK over five years in a sign of its increasing focus on Britain.
- The Telegraph
UK pharma giants pledge £430m investment in France after Macron charm offensive
Britain’s two biggest pharmaceutical companies have pledged £430m of investment in France after a charm offensive by Emmanuel Macron.
- Zacks
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.
